SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Paolo Gubellini, Christophe Melon, Elena Dale, Dario Doller, Lydia Kerkerian-Le Goff, Distinct effects of mGlu4 receptor positive allosteric modulators at corticostriatal vs. striatopallidal synapses may differentially contribute to their antiparkinsonian action, Neuropharmacology, 2014, 85, 166

    CrossRef

  2. 2
    Marion S. Mercier, David Lodge, Group III Metabotropic Glutamate Receptors: Pharmacology, Physiology and Therapeutic Potential, Neurochemical Research, 2014, 39, 10, 1876

    CrossRef

  3. 3
    Magdalena Zaniewska, Edmund Przegaliński, Małgorzata Filip, Andrzej Pilc, Darío Doller, Inhibitory actions of mGlu4 receptor ligands on cocaine-, but not nicotine-, induced sensitizing and conditioning locomotor responses in rats, Pharmacological Reports, 2014, 66, 2, 205

    CrossRef

  4. 4
    Krystyna Ossowska, Jadwiga Wardas, Klemencja Berghauzen-Maciejewska, Urszula Głowacka, Katarzyna Kuter, Andrzej Pilc, Stevin H. Zorn, Dario Doller, Lu AF21934, a positive allosteric modulator of mGlu4 receptors, reduces the harmaline-induced hyperactivity but not tremor in rats, Neuropharmacology, 2014, 83, 28

    CrossRef

  5. 5
    Lucyna Pomierny-Chamioło, Kinga Rup, Bartosz Pomierny, Ewa Niedzielska, Peter W. Kalivas, Małgorzata Filip, Metabotropic glutamatergic receptors and their ligands in drug addiction, Pharmacology & Therapeutics, 2014, 142, 3, 281

    CrossRef

  6. 6
    Regina Ėmužytė, Regina Firantienė, Sofija Sasnauskienė, Danutė Kalibatienė, Odeta Kinčinienė, PADIDĖJĘS JAUTRUMAS MAISTO PRIEDAMS: GLUTAMATO KLINIKINIAI ASPEKTAI, Medicinos teorija ir praktika, 2014, 20, 4, 324

    CrossRef

  7. 7
    Graziella Madeo, Tommaso Schirinzi, Giuseppina Martella, E. Claudio Latagliata, Francesca Puglisi, Jie Shen, Enza Maria Valente, Mauro Federici, Nicola B. Mercuri, Stefano Puglisi-Allegra, Paola Bonsi, Antonio Pisani, PINK1 heterozygous mutations induce subtle alterations in dopamine-dependent synaptic plasticity, Movement Disorders, 2014, 29, 1
  8. 8
    Clare Finlay, Susan Duty, Therapeutic potential of targeting glutamate receptors in Parkinson’s disease, Journal of Neural Transmission, 2014, 121, 8, 861

    CrossRef

  9. 9
    Boon Chin Heng, Dominique Aubel, Martin Fussenegger, An overview of the diverse roles of G-protein coupled receptors (GPCRs) in the pathophysiology of various human diseases, Biotechnology Advances, 2013, 31, 8, 1676

    CrossRef

  10. 10
    M. Amalric, S. Lopez, C. Goudet, G. Fisone, G. Battaglia, F. Nicoletti, J.-P. Pin, F.C. Acher, Group III and subtype 4 metabotropic glutamate receptor agonists: Discovery and pathophysiological applications in Parkinson's disease, Neuropharmacology, 2013, 66, 53

    CrossRef

  11. 11
    Limin Mao, Minglei Guo, Daozhong Jin, Bing Xue, John Q. Wang, Group III metabotropic glutamate receptors and drug addiction, Frontiers of Medicine, 2013, 7, 4, 445

    CrossRef

  12. 12
    James Bogenpohl, Adriana Galvan, Xing Hu, Thomas Wichmann, Yoland Smith, Metabotropic glutamate receptor 4 in the basal ganglia of parkinsonian monkeys: Ultrastructural localization and electrophysiological effects of activation in the striatopallidal complex, Neuropharmacology, 2013, 66, 242

    CrossRef

  13. 13
    Khaled-Ezaheir Bennouar, Michelle A. Uberti, Christophe Melon, Maria D. Bacolod, Hermogenes N. Jimenez, Manuel Cajina, Lydia Kerkerian-Le Goff, Darío Doller, Paolo Gubellini, Synergy between l-DOPA and a novel positive allosteric modulator of metabotropic glutamate receptor 4: Implications for Parkinson's disease treatment and dyskinesia, Neuropharmacology, 2013, 66, 158

    CrossRef

  14. 14
    Karen J. Gregory, Meredith J. Noetzel, Colleen M. Niswender, Oligomerization and Allosteric Modulation in G-Protein Coupled Receptors, 2013,

    CrossRef

  15. 15
    Craig W Lindsley, Corey R Hopkins, Metabotropic glutamate receptor 4 (mGlu4)-positive allosteric modulators for the treatment of Parkinson's disease: historical perspective and review of the patent literature, Expert Opinion on Therapeutic Patents, 2012, 22, 5, 461

    CrossRef

  16. 16
    Peter J. Flor, Francine C. Acher, Orthosteric versus allosteric GPCR activation: The great challenge of group-III mGluRs, Biochemical Pharmacology, 2012, 84, 4, 414

    CrossRef

  17. 17
    Claude Forni, Olivier Mainard, Christophe Melon, Didier Goguenheim, Lydia Kerkerian-Le Goff, Pascal Salin, Portable microstimulator for chronic deep brain stimulation in freely moving rats, Journal of Neuroscience Methods, 2012, 209, 1, 50

    CrossRef

  18. 18
    Sylvain Célanire, Brice Campo, Recent advances in the drug discovery of metabotropic glutamate receptor 4 (mGluR4) activators for the treatment of CNS and non-CNS disorders, Expert Opinion on Drug Discovery, 2012, 7, 3, 261

    CrossRef

  19. 19
    Susan Duty, Targeting Glutamate Receptors to Tackle the Pathogenesis, Clinical Symptoms and Levodopa-Induced Dyskinesia Associated with Parkinson’s Disease, CNS Drugs, 2012, 26, 12, 1017

    CrossRef

  20. 20
    Jonathan W Dickerson, P Jeffrey Conn, Therapeutic potential of targeting metabotropic glutamate receptors for Parkinson’s disease, Neurodegenerative Disease Management, 2012, 2, 2, 221

    CrossRef

  21. 21
    Karen J. Gregory, Elizabeth N. Dong, Jens Meiler, P. Jeffrey Conn, Allosteric modulation of metabotropic glutamate receptors: Structural insights and therapeutic potential, Neuropharmacology, 2011, 60, 1, 66

    CrossRef

  22. 22
    Carrie K. Jones, Darren W. Engers, Analisa D. Thompson, Julie R. Field, Anna L. Blobaum, Stacey R. Lindsley, Ya Zhou, Rocco D. Gogliotti, Satyawan Jadhav, Rocio Zamorano, Jim Bogenpohl, Yoland Smith, Ryan Morrison, J. Scott Daniels, C. David Weaver, P. Jeffrey Conn, Craig W. Lindsley, Colleen M. Niswender, Corey R. Hopkins, Discovery, Synthesis, and Structure–Activity Relationship Development of a Series ofN-4-(2,5-Dioxopyrrolidin-1-yl)phenylpicolinamides (VU0400195, ML182): Characterization of a Novel Positive Allosteric Modulator of the Metabotropic Glutamate Receptor 4 (mGlu4) with Oral Efficacy in an Antiparkinsonian Animal Model, Journal of Medicinal Chemistry, 2011, 54, 21, 7639

    CrossRef

  23. 23
    Albert J. Robichaud, Darren W. Engers, Craig W. Lindsley, Corey R. Hopkins, Recent Progress on the Identification of Metabotropic Glutamate 4 Receptor Ligands and Their Potential Utility as CNS Therapeutics, ACS Chemical Neuroscience, 2011, 2, 8, 433

    CrossRef

  24. 24
    Antonio Drago, Concetta Crisafulli, Antonina Sidoti, Alessandro Serretti, The molecular interaction between the glutamatergic, noradrenergic, dopaminergic and serotoninergic systems informs a detailed genetic perspective on depressive phenotypes, Progress in Neurobiology, 2011, 94, 4, 418

    CrossRef

  25. 25
    Stephen P. East, Samantha Bamford, Matthias G.A. Dietz, Christian Eickmeier, Adam Flegg, Boris Ferger, Mark J. Gemkow, Ralf Heilker, Bastian Hengerer, Adrian Kotey, Pui Loke, Gerhard Schänzle, Hans-Dieter Schubert, John Scott, Mark Whittaker, Mildred Williams, Przemyslaw Zawadzki, Kai Gerlach, An orally bioavailable positive allosteric modulator of the mGlu4 receptor with efficacy in an animal model of motor dysfunction, Bioorganic & Medicinal Chemistry Letters, 2010, 20, 16, 4901

    CrossRef

  26. 26
    Susan Duty, Therapeutic potential of targeting group III metabotropic glutamate receptors in the treatment of Parkinson's disease, British Journal of Pharmacology, 2010, 161, 2